title: Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
abstract: BACKGROUND
  In previous trials, budesonide 6 mg/day was able to prolong the time to relapse in patients with quiescent Crohn's disease and budesonide 9 mg/day was effective in active disease with limited side effects. The aim of this study was to compare the effectiveness of budesonide 9 mg vs 6 mg once daily on the maintenance of remission and occurrence of adverse events.
  
  
  METHODS
  Double-blind, randomised trial in patients with Crohn's disease in remission. Patients were randomised to receive 6 mg/day or 9 mg/day of budesonide (Budenofalk) without concomitant treatment for Crohn's disease. Endpoints were the time to relapse and relapse rates after one year.
  
  
  RESULTS
  Seventy-six patients were randomised to 6 mg/day and 81 patients to 9 mg/day. Survival analysis showed no differences in the time to relapse. One-year relapse rates were not significantly different (6 mg group 24%; 9 mg group 19%). Any adverse event was reported in 61 and 68% of patients in the 6 mg and 9 mg groups, respectively; none of the 12 serious adverse events were drug related.
  
  
  CONCLUSIONS
  The one-year relapse rates were low and not significantly different between the group of patients treated with budesonide 6 mg vs 9 mg/day. Also, time to relapse and the number of adverse events were similar in both treatment groups.
authors.affiliation: Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. d.dejong@mdl.umcn.nl
authors.forename: D J
authors.initials: DJ
authors.lastname: de Jong
authors.forename: D J
authors.initials: DJ
authors.lastname: Bac
authors.forename: G
authors.initials: G
authors.lastname: Tan
authors.forename: S Y
authors.initials: SY
authors.lastname: de Boer
authors.forename: I L F
authors.initials: IL
authors.lastname: Grabowsky
authors.forename: J B M J
authors.initials: JB
authors.lastname: Jansen
authors.forename: R
authors.initials: R
authors.lastname: Greinwald
authors.forename: T H J
authors.initials: TH
authors.lastname: Naber
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D055502:Secondary Prevention; D016019:Survival Analysis
chemical_list: D000893:Anti-Inflammatory Agents; D019819:Budesonide